The Genome Sequencing Unit leverages next-generation sequencing (NGS) technologies to support outbreak investigations, pathogen identification, and antimicrobial resistance profiling. Our state-of-the-art workflows integrate both amplicon-based and hybrid-capture methods on platforms such as the Illumina MiSeq.
Core Capabilities & Technologies
- Advanced NGS workflows including Illumina Microbial Amplicon Prep (IMAP) and hybrid-capture target enrichment.
- Robust bioinformatic analysis using platforms such as Illumina DRAGEN, CLC Genomics Workbench, and TerraBio.
- Quality control metrics routinely achieving high Q30 scores and optimal read depths for accurate variant calling.
- Integrated systems ensuring seamless data transfer and interoperability with clinical informatics.
Recent Projects and Initiatives
- Mpox Virus Sequencing: Validated an NGS workflow for detecting and classifying hMPXV clades using genome-specific primers on the MiSeq.
- HIV Genome Sequencing & DR Mutation Analysis: Developed streamlined protocols for HIV genotyping, enabling detection of drug resistance mutations from specimens with moderate viral loads.
- SARS-CoV-2 & Multiplex PCR Development: Ongoing validation of sequencing assays to enhance pathogen surveillance and outbreak response.
- Infrastructure Enhancements: Recent system upgrades and improved instrument connectivity have augmented our sequencing capacity and data interoperability.
Impact on Public Health
Our integrated sequencing efforts provide pivotal data for tracking pathogen evolution and informing public health interventions. By rapidly identifying variants and detecting resistance mutations, the Genome Sequencing Unit contributes to targeted outbreak response and the strategic allocation of resources.
